[{"id":"2c9d4247-97d3-4cff-bce6-48a72101574c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04282044","created_at":"2021-01-18T20:47:23.693Z","updated_at":"2024-07-02T16:35:20.161Z","phase":"Phase 1","brief_title":"Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies","source_id_and_acronym":"NCT04282044","lead_sponsor":"BioEclipse Therapeutics","biomarkers":" HER-2 • ER • PGR","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV • CRX100"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/08/2021","start_date":" 01/08/2021","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-02-08"}]